Clinical Use of Recombinant Factor VIII Fc and Recombinant Factor IX Fc in Patients with Hemophilia A and B

被引：0
|
作者：
Wang, Cassandra
Young, Guy
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3665
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [22] Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A
    Sattler, Laurent
    Raissi, Ahlem
    Fornoff, Damien
    Gerout, Anne-Cecile
    Feugeas, Olivier
    Grunebaum, Lelia
    Desprez, Dominique
    ANNALES DE BIOLOGIE CLINIQUE, 2020, 78 (01) : 35 - 46
  • [23] Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients
    Liu, Bin
    Wang, Xiaoshan
    Li, Xueqin
    Yan, Haixia
    Wang, Shuya
    Zhu, Xi
    Wang, Pengju
    Gao, Jie
    Wang, Yali
    Su, Hongsheng
    BLOOD, 2018, 132
  • [24] Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
    Pochopien, Michal
    Tytula, Anna
    Toumi, Mondher
    Falk, Aletta
    Martone, Nicoletta
    Hakimi, Zalmai
    Eriksson, Daniel
    ADVANCES IN THERAPY, 2024, 41 (06) : 2307 - 2323
  • [25] Clinical study program to evaluate long-lasting recombinant factor VIII and IX FC fusion factors for paediatric use
    Kulkarni, R.
    Liesner, R.
    Fischer, K.
    Young, G.
    Foley, I.
    Allen, G.
    Krassova, S.
    Dumont, J.
    Nugent, K.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2013, 19 : 32 - 32
  • [26] Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
    Georgescu, Maria T.
    Moorehead, Paul C.
    Liu, Tongyao
    Dumont, Jennifer
    Scott, David W.
    Hough, Christine
    Lillicrap, David
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [27] Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
    Shapiro, Amy D.
    Kulkarni, Roshni
    Ragni, Margaret V.
    Chambost, Herve
    Mahlangu, Johnny
    Oldenburg, Johannes
    Nolan, Beatrice
    Ozelo, Margareth C.
    Foster, Meredith C.
    Willemze, Annemieke
    Barnowski, Christopher
    Jain, Nisha
    Winding, Bent
    Dumont, Jennifer
    Lethagen, Stefan
    Barnes, Chris
    Pasi, K. John
    BLOOD ADVANCES, 2023, 7 (13) : 3049 - 3057
  • [28] Improved pharmacokinetics and bleeding efficacy of recombinant Factor IX Fc-XTEN in hemophilia-B mice
    Van der Flier, Arjan
    Ismail, Ayman
    Liu, Zhan
    Liu, Lucy
    Simpson, Allison
    Seth-Cchabra, Ekta
    Schellenberger, Volker
    Loh, Christine
    Light, David
    Peters, Robert
    HAEMOPHILIA, 2016, 22 : 19 - 19
  • [29] Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China
    Zhou, Ting
    Wang, Shuyue
    Zhang, Yao
    Wu, Runhui
    Li, Hongchao
    PEDIATRIC BLOOD & CANCER, 2023, 70 (06)
  • [30] FACTOR CONSUMPTION FOR PROPHYLAXIS AND TREATMENT OF BLEEDING: RECOMBINANT FACTOR IX FC FUSION PROTEIN COMPARED WITH CONVENTIONAL RECOMBINANT FACTOR IX
    Iorio, A.
    Krishnan, S.
    Myren, K.
    Lethagen, S.
    McCormick, N.
    Kamer, P.
    VALUE IN HEALTH, 2015, 18 (07) : A660 - A660
12345